微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 37.52% | -3.25% | -3.96% | 69/159 | 48.56% | 首药控股 | 96.95% | 行业排名> |
| 2026-06-30 | 39.06% | 0.51% | 6.68% | 95/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 36.62% | -6.36% | -7.24% | 96/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 39.48% | -1.64% | 1.8% | 92/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 38.78% | -3.28% | -0.22% | 95/159 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 38.86% | -9.39% | -0.61% | 94/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 39.1% | -1.6% | -2.57% | 95/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 40.13% | -10.04% | 0.1% | 102/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 40.09% | -11.85% | -6.53% | 98/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 42.89% | -10.6% | 7.93% | 92/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 39.74% | -13.08% | -10.93% | 93/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 44.61% | -22.07% | -1.91% | 95/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 45.48% | -23.72% | -5.2% | 91/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 47.98% | -19.73% | 4.93% | 85/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 45.72% | -24.96% | -20.13% | 88/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 57.25% | -11.47% | -3.99% | 67/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 59.63% | -7.3% | -0.24% | 55/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 59.77% | -13.15% | -1.91% | 58/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 60.93% | -7.09% | -5.77% | 54/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 64.66% | -14.23% | 0.53% | 53/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 64.32% | -21.18% | -6.54% | 47/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 68.82% | -16.48% | 4.95% | 39/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 65.58% | -21.97% | -13.02% | 36/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 75.39% | 3.11% | -7.62% | 29/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 81.61% | 13.57% | -0.96% | 19/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 82.4% | 20.19% | -1.95% | 13/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 84.04% | 30.98% | 14.93% | 12/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 73.12% | 4.67% | 1.75% | 31/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 71.86% | 1.89% | 4.82% | 25/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 68.56% | -0.24% | 6.85% | 31/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 64.16% | 2% | -8.15% | 32/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 69.85% | 31.56% | -0.96% | 35/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 70.53% | 2% | 2.62% | 22/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 68.72% | 2% | 29.44% | 24/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 53.1% | 64.55% | 64.55% | 57/159 | 52.25% | 贝达药业 | 95.54% | 行业排名> |
| 2016-12-31 | 32.27% | 39.51% | 39.51% | 84/159 | 48.17% | 贝达药业 | 95.74% | 行业排名> |